Phase 1 Kidney Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• The patient (and their legal guardian if appropriate) must fully understand the study, agree to take part voluntarily, and sign a written consent form. A separate consent form for EGFR testing is also required before screening begins.
• Patients who are between 2 and 18 years old at the time of consent.
• Patients whose doctors estimate they have a life expectancy of at least 3 months.
• Patients who have a laboratory-confirmed solid tumour that has come back, is not responding to treatment, or has spread, and whose tumour tests positive for a protein called EGFR. The tumour must be one of the following types: head and neck squamous cell carcinoma, nasopharyngeal carcinoma, or lymphoepithelial carcinoma that got worse during or after at least one treatment course involving platinum-based chemotherapy and a type of immunotherapy (PD-1/PD-L1 inhibitor); rhabdomyosarcoma; neuroblastoma; medulloblastoma; Wilms tumour; atypical teratoid/rhabdoid tumours (AT/RTs); diffuse intrinsic pontine gliomas (DIPGs); or another EGFR-positive solid tumour type considered eligible by the trial doctor.
• Patients who have at least one tumour that can be measured by CT or MRI scan, meeting specific size requirements set out in standard measurement guidelines (confirm with trial site).
• Patients whose general health and ability to carry out daily activities falls within an acceptable range on a standard medical scale (confirm with trial site).
• Patients whose bone marrow is producing enough blood cells, meeting specific blood count levels as assessed by a doctor — with slightly different thresholds allowed for patients whose bone marrow is directly affected by the cancer.
• Patients whose liver and kidneys are functioning well enough, based on blood test results meeting specific levels — with slightly different thresholds allowed if the cancer has spread to the liver.

Who may not be able to join:

• Patients who have had a known allergic reaction to any ingredient in the study drug, Becotatug Vedotin (MRG003).
• Patients who have cancer that has spread to the brain or spinal cord and is causing active symptoms.
• Patients who have had another type of cancer in the past, unless it was a limited skin cancer that was fully removed, cervical pre-cancer, or any previous cancer that has been in complete remission for 3 or more years without any treatment. Note: a history of melanoma at any stage is specifically excluded.
• Patients who have significant liver disease, including a positive test for hepatitis C antibodies or active hepatitis B with high virus levels in the blood.
• Patients who have a known HIV infection.
• Patients who have a history of serious eye conditions, such as severe dry eye syndrome or a condition called exposure keratitis.
• Patients who have severe or uncontrolled medical conditions, including lung inflammation (interstitial lung disease or pneumonitis) or an active autoimmune disease that requires ongoing treatment with immune-suppressing medicines.
• Patients who have significant heart problems, including certain types of heart failure, uncontrolled irregular heartbeat, or an abnormal heart rhythm reading on an ECG beyond specific thresholds (confirm with trial site).
• Patients who received systemic cancer treatment (such as chemotherapy, immunotherapy, targeted therapy, or biological therapy) within the 3 weeks before the first dose of the study drug, and whose side effects from that treatment have not settled back to a mild level.
• Patients who had a major surgical procedure within the 3 weeks before the first dose of the study drug.
• Patients who have a surgery planned during the course of the study, or any surgery the trial doctor considers necessary.
• Patients who experienced severe skin reactions from a previous EGFR-targeted treatment, or who have a chronic skin condition requiring ongoing oral or intravenous treatment.
• Patients who have any other medical condition that, in the trial doctor's judgement, would increase the risk of harm or make it difficult to complete the study.

Important: Always verify eligibility with the trial site directly before applying.